DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1d ago
524516 logo

Bacil Pharma LimitedBSE:524516 Stock Report

Market Cap ₹307.7m
Updated 1d ago
Share Price
n/a
1Y-43.6%
7D10.6%
1D3.8%
Portfolio Value
​
View

Bacil Pharma Limited

BSE:524516 Stock Report

Market Cap: ₹307.7m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Bacil Pharma (524516) Stock Overview

Develops, manufactures, and distributes pharmaceuticals products in India. More details

524516 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap (₹308M)

Highly volatile share price over the past 3 months compared to the Indian market

Makes less than USD$1m in revenue (₹0)


524516 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW430,343 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
430,343 investors already sharing narratives
₹
Current Price
₹21.44n/aintrinsic discount
Est. Revenue
$
PastFuture-40m11m2016201920222025202620282031Revenue ₹1.0Earnings ₹0
Advanced
View all narratives

Bacil Pharma Limited Competitors

Gujarat Terce Laboratories

Symbol: BSE:524314
Market cap: ₹286.6m

Goldline Pharmaceutical

Symbol: BSE:544759
Market cap: ₹335.0m

JFL Life Sciences

Symbol: NSEI:JFLLIFE
Market cap: ₹344.8m

Murae Organisor

Symbol: BSE:542724
Market cap: ₹353.2m

Price History & Performance

Summary of share price highs, lows and changes for Bacil Pharma
Historical stock prices
Current Share Price₹21.44
52 Week High₹61.80
52 Week Low₹10.65
Beta0.35
1 Month Change74.31%
3 Month Change-46.40%
1 Year Change-43.64%
3 Year Change187.01%
5 Year Change312.31%
Change since IPO634.25%

Recent News & Updates

Recent updates

Shareholder Returns

524516IN PharmaceuticalsIN Market
7D10.6%0.5%-0.3%
1Y-43.6%14.0%-3.0%

Return vs Industry: 524516 underperformed the Indian Pharmaceuticals industry which returned 14% over the past year.

Return vs Market: 524516 underperformed the Indian Market which returned -3% over the past year.

Price Volatility

Is 524516's price volatile compared to industry and market?
524516 volatility
524516 Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement5.7%
10% most volatile stocks in IN Market8.9%
10% least volatile stocks in IN Market3.4%

Stable Share Price: 524516's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: 524516's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
19872Chaitali Shahbacilpharma.co.in

Bacil Pharma Limited develops, manufactures, and distributes pharmaceuticals products in India. The company offers pharmaceutical formulations, including tablets, capsules, injectables, ointments, and specialty products. Bacil Pharma Limited was incorporated in 1987 and is based in Mumbai, India.

Bacil Pharma Limited Fundamentals Summary

How do Bacil Pharma's earnings and revenue compare to its market cap?
524516 fundamental statistics
Market cap₹307.73m
Earnings (TTM)₹8.70m
Revenue (TTM)n/a
35.4x
P/E Ratio
0.0x
P/S Ratio

Is 524516 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
524516 income statement (TTM)
Revenue₹0
Cost of Revenue₹0
Gross Profit₹0
Other Expenses-₹8.70m
Earnings₹8.70m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.61
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 524516 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 02:13
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bacil Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide